Insomnia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for insomnia. 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
8
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators in Insomnia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Eisai 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating insomnia. Each bar = one year. Y-axis scaled to peak year (6 patents).

2
31
6
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Dayvigo
LEMBOREXANT
 Eisai 8 60 — 2031-09-20

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8268848 Dayvigo method of use 68 2031-09-20
8268848 Dayvigo method of use 68 2031-09-20
10188652 Dayvigo method of use 62 2035-10-21
10188652 Dayvigo method of use 62 2035-10-21
11026944 Dayvigo formulation 55 2035-10-21
10702529 Dayvigo formulation 55 2035-10-21
10702529 Dayvigo formulation 55 2035-10-21
11026944 Dayvigo formulation 55 2035-10-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11026944 Dayvigo formulation 55 2035-10-21
10702529 Dayvigo formulation 55 2035-10-21
10702529 Dayvigo formulation 55 2035-10-21
11026944 Dayvigo formulation 55 2035-10-21
10188652 Dayvigo method of use 62 2035-10-21
10188652 Dayvigo method of use 62 2035-10-21
8268848 Dayvigo method of use 68 2031-09-20
8268848 Dayvigo method of use 68 2031-09-20

Related